Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-THK5351
- Development stage
- Phase 2
- Lead developer
- Tohoku University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
**[18F]THK-5351** is a novel quinoline-derived radiopharmaceutical developed as a positron emission tomography (PET) imaging agent for the detection of tau pathology in the brain. It demonstrates high binding selectivity and affinity for neurofibrillary tangles composed of paired helical filaments (PHFs) of tau protein, which are characteristic of Alzheimer's disease and other tauopathies. Compared to earlier tracers like 18F-THK5117, it exhibits improved pharmacokinetics with faster kinetics, higher contrast in PET imaging, and lower retention in subcortical white matter. The tracer has been shown to correlate with the amount of tau deposits in human brain samples and can also detect reactive astrogliosis associated with neurodegenerative changes. Originally discovered by Tohoku University and further developed by GE Healthcare along with Samsung Medical Center and Asan Medical Center, [18F]THK-5351 is primarily used for diagnostic purposes to aid early detection and monitoring of Alzheimer's disease progression[5][3][2][6].
- Brand names
- FluoroTau
- Other names
- 18F-THK5351THK-5351THK5351THK 5351[18F]THK-5351
02
Targets
MAOB (Monoamine oxidase B)Tau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on 18F-THK5351.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-THK5351.